Loading
A phase 2 trial of HF1K16 in glioma & glioblastoma, run by HighField Biopharmaceuticals Corporation, now recruiting.
A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma is a phase 2 interventional study registered as NCT07678684 by HighField Biopharmaceuticals Corporation, with 30 participants planned, started 2026-06-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: HF1K16.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/